This feature highlights changes in clinical trial organizations’ personnel.

Adaptive Biotechnologies

Adaptive Biotechnologies has named Mark Adams the company’s chief technical officer. Most recently, Adams was managing director of healthcare advanced analytics of SVB Leerink. Adaptive has also appointed Jyoti Palaniappan to senior vice president of clinical diagnostics. Palaniappan was chief commercial officer for Bigfoot Biomedical before joining Adaptive.

Aravive

Gail McIntyre is now CEO of Aravive, following Rekha Hemrajani’s resignation. McIntyre most recently served as Aravive’s chief scientific officer.

Barclays

Barclays has named Khaled Habayeb managing director of healthcare equity capital markets. Habayeb previously served as managing director of Deutsche Bank.

BioSpecifics

BioSpecifics has named Joseph Truitt interim CEO, replacing prior CEO J. Kevin Buchi. Truitt comes to BioSpecifics from Achillion Pharmaceuticals, where he also served as CEO.

Bolt Biotherapeutics

Edith Perez has been appointed to the role of chief medical officer of Bolt Biotherapeutics. Perez joins Bolt from Genentech, where she served as vice president and head of the company’s BioOncology-U.S. medical affairs unit.

Cardurion Pharmaceuticals

Peter Lawrence has been named CEO of Cardurion Pharmaceuticals. Prior to this appointment, Lawrence was president and chief operating officer of ArQule.

Cellectis

Carrie Brownstein has been appointed to the position of chief medical officer at Cellectis. Prior to taking this role, Brownstein was vice president of global clinical research and development as well as therapeutic area head for myeloid diseases at Celgene.

Crown Bioscience

Armin Spura has been named CEO of CrownBio. He most recently served as vice president of Asia Pacific and Greater China affairs at CareDx.

CytoDyn

Scott Kelly has been named CytoDyn’s chief medical officer and head of business development. Kelly has served as the company’s chairman of the board since December 2018.

DarioHealth

DarioHealth has appointed Omar Manejwala to the role of chief medical officer. Manejwala was most recently the chief medical officer of Catasys.

Evelo Biosciences

Evelo Biosciences has hired Neil Graham as the company’s chief development officer. Graham was most recently vice president of strategic program direction, immunology and inflammation at Regeneron.

Five Prime Therapeutics

Thomas Civik takes the helm of Five Prime Therapeutics as its CEO. Most recently, Civik was chief commercial officer of Foundation Medicine.

Morphic Therapeutic

Marc Schegerin has been named chief financial officer and chief operating officer of Morphic Therapeutic. Previously, Schegerin was chief financial officer, treasurer and head of strategy & communications of ArQule.

Notable

Cancer biotech Notable has named Laurie Heilmann CEO. Heilmann was most recently president of global life science and diagnostic solutions of CrownBio.

OncoResponse

Robert Lechleider has been named chief medical officer of biotech company OncoResponse. Previously, Lechleider was senior vice president of clinical development at Seattle Genetics. OncoResponse has also promoted Kamal Puri from vice president of research and development to the role of chief scientific officer.

Parker Institute for Cancer Immunotherapy

Frederic Pla has been named chief operating officer of Parker Institute for Cancer Immunotherapy. Pla was most recently chief operating officer of Genomic Health.

Seres Therapeutics

Seres Therapeutics has found its new executive vice president and chief medical officer in Lisa von Moltke, who most recently served as senior vice president and head of clinical development at Alkermes.

SOPHiA GENETICS

Lara Hashimoto has been named chief medical officer of data-driven biotech SOPHiA GENETICS. Prior to this role, Hashimoto was chief commercial officer at Roche Sequencing Solutions.

Summit Therapeutics

Robert Duggan has been named CEO of Summit Therapeutics. Duggan currently serves as board chairman of Pulse Biosciences.

Sutura Therapeutics

Sutura Therapeutics appointed Alex Smith to head of patient advocacy. Smith runs the Harrison’s Fund, a leading Duchenne Muscular Dystrophy charity.

TRACON Pharmaceuticals

TRACON Pharmaceuticals has appointed Shahe Garabedian to the role of senior vice president of quality assurance. Garabedian was vice president of quality at Arena Pharmaceuticals prior to this role.